FDA approves lower dose of Lilly-Incyte arthritis drug
(Reuters) - The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Arthritis | Food and Drug Administration (FDA) | Health | Rheumatoid Arthritis | Rheumatology